Tat protein, the transactivating factor of the human immunodeficiency virus type 1 (HIV-1), 1 is released from HIV-1 infected cells (1) . Extracellular Tat can enter the cell and nucleus to stimulate the transcriptional activity of HIV-LTR (2) . Moreover, extracellular Tat induces several biological effects on uninfected target cells (3) . Tat has been implicated in pathological processes associated to AIDS, including Kaposi's sarcoma (KS) (4) . Indeed, KS spindle cell xenografts grow faster in Tat transgenic mice than in non-transgenic animals (5) . Also, Tat-overexpressing T53 cells, derived from an adenocarcinoma of a BKV/Tat transgenic mouse (6) , are angiogenic and induce highly vascularized tumors in nude mice that resemble KS (7, 8) .
Tat binds the polyanionic glycosaminoglycans (GAGs) heparin and heparan sulfate via its basic domain (9, 10) . The binding of extracellular Tat to heparan sulfate proteoglycans (HSPGs) mediates cell surface interaction (11) and accumulation in the extracellular matrix (ECM) (12) . Also, HSPGs are required for Tat internalization and consequent HIV-LTR transactivation (13) . Conversely, the interaction of extracellular Tat with free GAGs inhibits cellular uptake and HIV-LTR transactivating activity in HL3T1 and CHO cells (13, 14) , affects its mitogenic and protease-inducing activities in T53 cells (14, 15) , and modulates its angiogenic activity in vivo (11) .
Several polyanionic compounds inhibit HIV-1 replication by preventing the binding of the virus to target cells (16) . Some of these compounds, including unmodified heparin, heparan sulfate, and suramin-like distamycin A derivatives, although not dextran sulfate, ␤-cyclodextrin, chemically desulfated or low molecular weight heparins, also bind extracellular Tat and inhibit its biological activity in vitro (9, 10, 14, 17) and in vivo (18) . Thus, selected polyanionic molecules endowed with the capacity to affect HIV life cycle at different levels can be exploited for the development of novel "multitarget" anti-AIDS drugs.
The heparin analog xylanopolyhydrogensulfate (pentosan polysulfate, PPS) prevents the interaction of HIV-1 with target cells (19) and inhibits its reverse transcriptase activity (20) . Also, PPS affects tumorigenicity and angiogenic potential of KS xenografts in nude mice (21) . The capacity of PPS to inhibit the biological activity of various heparin-binding angiogenic growth factors, including fibroblast growth factor-2 (FGF-2) (22) (23) (24) (25) raises the possibility that PPS may interfere additionally with extracellular Tat protein. To assess this possibility, as a part of a long-term project aimed to identify polyanionic multitarget HIV-Tat antagonists (9, 10, (13) (14) (15) 17) , we evaluated the capacity of PPS to bind Tat protein and to inhibit the biological activity of extracellular Tat in vitro and in vivo. The results demonstrate that PPS binds Tat and prevents its inter-action with heparin. Accordingly, PPS inhibits cell surface interaction and internalization of extracellular Tat causing the inhibition of HIV-LTR-transactivating activity, mitogenic capacity, and angiogenic potential of the protein. These observations identify PPS as a prototypic molecule for the design of novel multitarget drugs for the treatment of AIDS and AIDSassociated pathologies.
EXPERIMENTAL PROCEDURES
Reagents-Recombinant HIV-1 Tat (86-amino acid isoform) was expressed in Escherichia coli as glutathione S-transferase (GST) fusion protein (9) . GST⅐Tat was also fused at its C terminus to the green fluorescent protein (GFP) (14) . The GST and GFP moieties do not interfere with LTR-transactivating activity and heparin-binding capacity of Tat (13, 14) . Pentosan polysulfate was from Sigma (St Louis, MO). Heparin was from Laboratori Derivati Organici SpA, (Milan, Italy). ␤-Cyclodextrin tetradecasulfate was from Glycores 2000 (Milan, Italy). Fluorescein-labeled bovine serum albumin (FITC-BSA) was kindly provided by Prof. S. Marchesini (University of Brescia, Italy).
BIAcore Binding Assay-Surface plasmon resonance (SPR) was used to measure changes in refractive index caused by the capacity of free PPS to bind GST⅐Tat and prevent its interaction with heparin immobilized to a BIAcore sensor chip (26, 27) . To this purpose, size-defined heparin (9 kDa) was biotinylated on its reducing end, and a flow cell of an F1 sensor chip was activated with streptavidin. Then, biotinylated heparin was allowed to react with the streptavidin-coated sensor chip. GST⅐Tat alone or in the presence of increasing concentrations of PPS was then injected over the heparin surface for 5 min to allow the association of the protein with heparin and then washed until dissociation was observed. The SPR signal was expressed in terms of resonance units (RU).
Preparation of 3 H-labeled Heparin and GST⅐Tat Affinity Chromatography-Heparin was 3 H-labeled as described (28) with a specific radioactivity of 5,000 cpm/nmol. To assay the capacity of PPS to compete with [ 3 H]heparin for the binding to immobilized GST⅐Tat, [ 3 H]heparin was loaded onto a GST⅐Tat-glutathione-agarose column in the presence of increasing concentrations of PPS, ␤-cyclodextrin, or unlabeled heparin. The column was then washed with phosphate-buffered saline and eluted with 2.0 M NaCl. Radioactivity in the eluate was measured in a liquid scintillation counter.
Cell Cultures-HL3T1 cells are derived from HeLa cells and contain integrated copies of pL3CAT, a plasmid in which the chloramphenicol acetyltransferase (CAT) bacterial gene is driven by HIV-1 LTR (29) . The T53 cell line was established from adenocarcinoma of skin adnexa of Tat transgenic mice and secretes biologically active Tat (6, 7). T53 Tat-less cells, obtained by subcloning T53 cells, do not produce detectable amounts of extracellular Tat but retain the capacity to proliferate when exposed to exogenous Tat (14) . All cell types were grown in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal calf serum (DMEM/FCS, Life Technologies, Inc., Grand Island, NY).
LTR-CAT Transactivation Assay-HL3T1 cells were seeded in 24-well dishes at 20,000 cells/cm 2 in DMEM/FCS. After 24 h, cells were incubated for another 24 h period in fresh DMEM/FCS and 100 M chloroquine in the absence or in the presence of 200 ng/ml of GST⅐Tat and increasing concentrations of the polysulfated compound that was to be tested. Then, conditioned medium was removed, and cells were incubated for an additional 24 h in DMEM/FCS. In some experiments, subconfluent cultures of HL3T1 cells were lipofectin-transfected with 2 g/ml of pCEP-Tat expression vector harboring the HIV-1 Tat cDNA (kindly provided by Dr. A. Gualandris, University of Torino, Italy). Five hours after transfection, cells were washed and incubated for another 24 h in DMEM/FCS in the absence or presence of PPS (100 nM). At the end of the incubation, the amount of CAT protein present in the cell extracts was determined using the CAT ELISA kit (Roche Molecular Biochemicals).
T53 Cell Proliferation Assays-T53 Tat-less cells were seeded in 96-well dishes at 10,000 cells/cm 2 in DMEM/FCS. After 24 h, cells were incubated for another 24 h in fresh DMEM/FCS in the absence or presence of 200 ng/ml of GST⅐Tat and increasing concentrations of the polysulfated compound being tested. At the end of the incubation, cells were trypsinized and counted in a Burker chamber.
Internalization of GST⅐Tat⅐GFP in HL3T1 Cells-HL3T1 cells adherent to glass coverslips were incubated for 6 h at 37°C in DMEM/FCS containing 400 ng/ml of GST⅐Tat⅐GFP in the absence or presence of increasing concentrations of the polysulfated compound being tested. At the end of the incubation, the cells were washed and fixed. GST⅐Tat⅐GFP internalization was quantified by computerized image analysis as described (14) .
Binding of GST⅐Tat⅐GFP to T53 Tat-less Cells-T53 Tat-less cells adherent to glass coverslips (20,000/cm 2 ) were incubated for 6 h at 37°C in DMEM/FCS and 400 ng/ml of GST⅐Tat⅐GFP in the absence or presence of PPS (1 M). At the end of the incubation, the medium was removed, and cells were washed and fixed as described (8) . Observations were carried out in a Nikon photomicroscope equipped for epifluorescence.
Chick Embryo Chorioallantoic Membrane (CAM) Assay-The CAM assay was performed as described (30) . Briefly, a window was opened in the egg shell of 3-day-old fertilized chicken eggs. At day 8, gelatin sponges (Gelfoam; Upjohn Co., Kalamazoo, MI) were implanted on the CAMs and adsorbed with 10 l of phosphate-buffered saline alone or containing GST or GST⅐Tat (both at 400 ng/sponge) in the absence or presence of PPS (25 g/sponge; 5-6 embryos per group). In parallel experiments, the sponges were adsorbed with 10 l of DMEM/FCS alone or containing T53 cells (6 ϫ 10 4 cells/sponge) in the absence or presence of 25 g of PPS (5-6 embryos per group). After 4 days, CAMs were observed in ovo under a Zeiss SR stereomicroscope, and the angiogenic response was scored by two investigators without knowledge of the samples tested and graded on an arbitrary scale of 0 -4ϩ, with 0 representing no angiogenic response and 4ϩ representing the strongest activity.
RESULTS

PPS Binds
Tat Protein-To assess its ability to interact with Tat protein, PPS was evaluated for the capacity to prevent GST⅐Tat binding to biotinylated heparin immobilized onto a streptavidin-activated BIAcore sensor chip. Preliminary experiments were performed to assess the ability of GST⅐Tat to bind immobilized heparin. In a typical experiment, increasing concentrations of GST⅐Tat were injected over the heparin surface, and a set of sensograms was obtained (Fig. 1A ). An association rate constant (k on ) equal to 4. , 5.9, 3.9, 2.6, and 0 g/ml for 5 min over a BIAcore sensor chip containing streptavidin plus 120 resonance units (RU) of immobilized biotinylated heparin. B, GST⅐Tat (solid line) or GST alone (dotted line) (both at 5 g/ml) were injected for 5 min over a streptavidin surface or a streptavidin-heparin surface, respectively. In both experiments, the responses (in RU) were recorded as a function of time.
formation of highly stable complexes. This interaction is specific because GST protein devoid of the Tat moiety does not bind to immobilized heparin, and GST⅐Tat does not bind to a streptavidin surface in the absence of immobilized heparin (Fig. 1B) . In some experiments, the association phase of GST⅐Tat-heparin interaction was allowed to proceed to equilibrium, and the data were used to calculate an affinity value independent of the kinetics of binding. This analysis demonstrates that GST⅐Tat-heparin interaction occurs with a K d equal to 58 nM, a value consistent with our kinetics analysis and with previous determinations obtained with different experimental approaches (14) . On this basis, we evaluated the capacity of PPS to compete with immobilized heparin for the binding to GST⅐Tat. To this purpose, increasing concentrations of PPS were preincubated with GST⅐Tat and then injected onto the heparin-coated sensor chip. As shown in Fig. 2A , PPS causes a dose-dependent inhibition of GST⅐Tat-heparin interaction, with an ID 50 equal to 120 nM. The binding data allowed the calculation of the relative affinity of PPS-GST⅐Tat interaction (K d is equal to 9.0 nM).
PPS was also evaluated for its capacity to compete with free [ 3 H]heparin for the binding to GST⅐Tat immobilized onto glutathione-agarose beads. As shown in Fig. 2B , PPS inhibits the binding of [ 3 H]heparin to GST⅐Tat in a dose-dependent manner with a potency similar to unlabeled heparin (ID 50 equal to 100 and 300 nM, respectively). Under the same experimental conditions, the polysulfated ␤-cyclodextrin, here used as a negative control (10), did not prevent the binding of [ 3 H]heparin to immobilized GST⅐Tat even when tested at doses as high as 300 M (Fig. 2B) . Taken together, the data demonstrate that PPS binds Tat in a specific manner with an affinity comparable with that of Tat-heparin interaction.
PPS Inhibits Cell Internalization and HIV-LTR Transactivating Activity of Extracellular
Tat-The capacity of PPS to abolish the interaction of Tat with immobilized heparin raised the possibility that PPS may prevent the binding of extracellular Tat to cell-associated heparin-like HSPGs that are required for its internalization (13) . To assess this hypothesis, we evaluated the capacity of PPS to inhibit cell internalization of GST⅐Tat conjugated to fluorescent GFP. As shown in Fig. 3 , PPS inhibits the internalization of GST⅐Tat⅐GFP in HL3T1 cells in a dose-dependent manner with an ID 50 equal to 1.0 nM, close to that observed for heparin (ID 50 ϭ 3.0 nM). When tested under the same experimental conditions, PPS does not affect the uptake of fluorescein-labeled BSA, as assessed by image analysis of the total fluorescence internalized by HL3T1 cells incubated with 400 ng/ml of FITC-BSA in the absence or in the presence of 100 nM PPS (1.21 Ϯ 0.48 and 1.92 Ϯ 0.67 arbitrary units, respectively). It must be pointed out that ϳ90% of GST⅐Tat⅐GFP or FITC-BSA remained associated to the cells after a 2.0 M NaCl wash of the cell monolayer, thus confirming the intracellular localization of the fluorescent proteins (data not shown). The specificity of PPS-Tat interaction was demonstrated further by the inability of polysulfated ␤-cyclodextrin to affect Tat internalization (Fig. 3A) .
In agreement with its capacity to inhibit Tat internalization, PPS abolished the LTR-CAT transactivating activity exerted by GST⅐Tat in HL3T1 cells whereas ␤-cyclodextrin was ineffective (Fig. 4A) . It should be noted that 100 nM PPS did not affect the basal levels of LTR-CAT transactivation measured in HL3T1 cells incubated in the absence of GST⅐Tat (0.166 Ϯ 0.036 and 0.170 Ϯ 0.034 A 405 nm units for PPS-untreated and -treated cells, respectively). Also, no inhibition of LTR-CAT transactivation was observed when Tat was expressed as an intracellular protein in PPS-treated HL3T1 cells following transient transfection with an expression vector harboring the HIV-1 Tat cDNA (Fig. 4B ). These data demonstrate that the antagonist effect of PPS on GST⅐Tat-mediated LTR-CAT transactivation is specific and depends on an extracellular interaction with Tat protein.
To investigate further the mechanism(s) of action of PPS on extracellular Tat activity, PPS was administered to HL3T1 cells together with GST⅐Tat or at different times after the transactivating factor. As shown in Fig. 4C , the LTR-transactivating activity of Tat is completely abolished when PPS was administered within the first 2 h following the beginning of GST⅐Tat treatment. Addition of PPS to the cell culture medium at later time points instead causes a progressive decrease of its antagonist activity that depends on an early interaction with extracellular Tat. Similar results were obtained when PPS was replaced by heparin as Tat antagonist (Fig. 4C) . of a tat transgenic mouse (6) . We have characterized a subclone of T53 cells, named T53 Tat-less cells, that does not produce significant amounts of endogenous Tat but that retains the capacity to proliferate when exposed to exogenous Tat (14) . Also, the mitogenic activity exerted by Tat in T53 Tat-less cells is inhibited by heparin (14) . On this basis, the Tat antagonist activity of PPS was evaluated in this model. As shown in Fig.  5A , PPS inhibits the binding of GST⅐Tat⅐GFP to the surface of T53 Tat-less cells. Approximately 80% of cell-associated fluorescence was removed by a 2.0 M NaCl wash of the cell monolayer, thus confirming the extracellular nature of GST⅐Tat⅐GFP (data not shown). In agreement with these observations, PPS inhibits the mitogenic activity exerted by GST⅐Tat with a potency similar to that shown by heparin (ID 50 equal to 1.0 nM for both compounds) (Fig. 5B) . On the contrary, PPS does not affect T53 Tat-less cell proliferation induced by 10% FCS (Fig. 5B) .
PPS Inhibits Cell Surface Binding and Mitogenic Activity of Extracellular Tat-Endogenous
PPS Inhibits the Angiogenic Activity of Extracellular TatExtracellular Tat is endowed with angiogenic potential in vivo (7, 8, 11, 17) . Accordingly, GST⅐Tat induces neovascularization in the chick embryo chorioallantoic membrane (CAM) (Fig. 6A) . This activity is specific because GST devoid of the Tat moiety does not exert any effect when tested under the same experimental conditions (Fig. 6A) . In agreement with its in vitro antagonist activity, PPS caused a significant inhibition of GST⅐Tat-induced neovascularization when tested in vivo at the dose of 25 g/ implant (Fig. 6A) . PPS also inhibited the unstimulated, physiological vascularization of the CAM that is mediated by endogenous FGF-2 produced by the chick embryo (31) .
Tat-overexpressing parental T53 cells exert a significant angiogenic response when implanted on the top of the CAM (Fig.  6B) , a biological effect because of the release of bioactive Tat protein (7, 8, 17) . Again, PPS was able to suppress neovascularization induced by T53 cells when tested at the dose of 25 g/implant (Fig. 6, B and C) . DISCUSSION Tat protein has been considered as a target for anti-AIDS therapies aimed to block its intracellular interaction with RNA target structures and various intracellular cofactors required for transactivation of the viral genome (32) . More recently, an increasing body of evidence point to a role for extracellular Tat in the progression of AIDS and AIDS-associated pathologies (3) . This suggests that the use of extracellular Tat antagonists may be of therapeutic benefit for AIDS patients. Accordingly, the development of anti-Tat vaccines has been undertaken (33, 34) . Also, in vitro and in vivo studies have underscored the possibility of using polysulfated/polysulfonated compounds as extracellular Tat antagonists (10, 14, 17, 18, 35) . Here, we provide experimental evidence that PPS binds extracellular Tat with high affinity (K d ϭ 9.0 nM), similar to the physiological
FIG. 3. Effect of PPS on GST⅐Tat⅐GFP internalization in HL3T1 cells.
A, subconfluent cell cultures were treated with GST⅐Tat⅐GFP (400 ng/ml) in the absence or presence of increasing concentrations of PPS (q), heparin (E), or polysulfated ␤-cyclodextrin (‚). Then, the amount of GST⅐Tat⅐GFP internalized was evaluated by image analysis. Data are expressed as percent of GST⅐Tat⅐GFP internalized in the absence of polysulfated molecules. Each point is the mean of 3-6 determinations performed in duplicate. The S.E. never exceeded 9 -16% of the mean value. B, microphotographs (original magnification ϫ 600) of HL3T1 cells treated with GST⅐Tat⅐GFP alone (a) or in the presence (b) of PPS (100 nM).
FIG. 4. Effect of PPS on the transactivating activity of GST⅐Tat in HL3T1 cells.
A, subconfluent cell cultures were treated with GST⅐Tat (200 ng/ml) in the presence of increasing concentrations of PPS (q), heparin (E), or polysulfated ␤-cyclodextrin (‚). Then, cell extracts were assayed for levels of CAT antigen by ELISA, and data were expressed as percent of the transactivating activity measured in cultures treated with GST⅐Tat alone. Each point is the mean Ϯ S.E. of 2-8 determinations in duplicate. B, subconfluent cell cultures were transiently transfected with the pCEP-Tat expression vector devoid (a) or harboring the HIV-1 Tat cDNA (b-d). After transfection, cells were incubated in fresh medium in the absence (a and b) or in the presence of PPS (c) or heparin (d), both at 100 nM. Then, cell extracts were assayed for the levels of CAT antigen by ELISA. Each point is the mean Ϯ S.E. of three determinations in duplicate. C, subconfluent cell cultures were treated with 200 ng/ml of GST⅐Tat. At the indicated periods of time after the beginning of GST⅐Tat treatment, cells were administered with PPS (q) or heparin (E) (both at 100 nM). Forty-eight hours after the beginning of GST⅐Tat treatment, cell extracts were assayed for levels of CAT antigen by ELISA, and data were expressed as percent of the transactivating activity measured in cultures treated with GST⅐Tat alone. Each point is the mean Ϯ S.E. of three determinations in duplicate.
ligand heparin (14) . This interaction inhibits the binding of Tat to free and surface-immobilized heparin. Accordingly, PPS inhibits cell internalization of extracellular Tat and its biological activity in different experimental models. However, PPS does not inhibit LTR-CAT transactivation exerted by endogenous intracellular Tat and does not affect FITC-BSA internalization. Also, PPS inhibits the mitogenic activity exerted by extracellular Tat in T53 cells without affecting cell proliferation induced by serum. Taken together these data support the hypothesis that the antagonist activity of PPS is mainly caused by a specific interaction with extracellular Tat protein.
The interaction of extracellular Tat with cell-associated HSPGs allows the accumulation of the bioactive protein in the ECM and mediates its interaction with the cell surface (11, 12) , leading to cell internalization of the protein and LTR-transactivation (13) . The capacity of PPS to prevent the binding of GST⅐Tat to immobilized heparin indicates that PPS may hamper HSPG-mediated interaction of extracellular Tat with target cells. Accordingly, PPS inhibits the internalization of extracellular Tat in HL3T1 cells and its association with the surface of T53 Tat-less cells. Consequently, PPS antagonizes the transactivating and mitogenic activity exerted by extracellular Tat in the two cell lines, respectively. Association with free heparin is required for the chemotactic and angiogenic activity of extracellular Tat (11) . Together with its ability to inhibit FGF-2-mediated angiogenesis, the capacity of PPS to prevent the binding of Tat to free heparin may contribute to the angiostatic activity exerted by PPS in vivo.
PPS retains its Tat antagonist activity when added to HL3T1 cells 2 h after the administration of the transactivating factor, when extracellular Tat is already bound to the cell surface (10) . This appears to be of particular importance when considering that significant amounts of Tat can be avidly sequestered by ECM HSPGs (12) , as indicated by the slow dissociation rate of the Tat-immobilized heparin complex. It should be pointed out that, at variance with PPS, thrombospondin-1 retains its Tat antagonist activity only when the transactivating factor is present in the extracellular environment as a free protein, being ineffective when Tat is bound to the cell surface (8) . It is also interesting to note that the high stability of the Tatheparin complex appears to be a unique feature of this transactivating factor. Indeed, different heparin-binding growth factors and cytokines, including FGF-2 (36), stromal cell-derived factor 1␣ (SDF-1␣) (27) , and RANTES, 2 dissociate rapidly from the GAG.
The capacity of sulfated GAGs and polysulfonated compounds to bind extracellular Tat and to inhibit its biological activity depends on the backbone structure and, at least in 2 H. Lortat-Jacob, unpublished observations. part, on the degree of sulfation (9, 10) . Indeed, a series of distamycin A derivatives structurally related to suramin but characterized by different chemical structure and degree of sulfation differ significantly for their Tat antagonist activity (10) . Here, we have demonstrated that PPS binds Tat and inhibits its biological activity with a potency similar to that shown by heparin and 1,000 times higher than that of suramin (10, 14) . These data indicate that the backbone structure of PPS presents its sulfate group(s) to Tat protein under optimal steric conditions, resembling more closely heparin interaction.
PPS inhibits the receptor binding and mitogenic activity of FGF-1 and FGF-2, being ineffective on cell proliferation mediated by IGF-1 or TGF-␣. In contrast, suramin exerts a nonselective inhibitory effect at doses 100 times higher than that of PPS (23) . Previous observations had shown that PPS binds also HIV gp120, thus preventing its interaction with cellular CD4 (19) , and inhibits HIV-induced syncytium formation (37) and lymphocyte-to-epithelial transmission of HIV-1 (38) . Moreover, PPS inhibits reverse transcriptase activity (20) . Here we demonstrate that PPS is a potent extracellular Tat antagonist at doses significantly lower than those required to inhibit blood coagulation (21) . Accordingly, phase I and II clinical trials have shown that PPS is well tolerated and may cause stabilization of the disease in AIDS-related KS patients (39 -41) . Taken together, the data indicate that PPS may represent a prototypic molecule for the design of novel multitarget extracellular Tat antagonists to be used for the treatment of AIDS and AIDSassociated pathologies. In particular, the potency and specificity shown by PPS in inhibiting the biological activity of Tat and FGF-2 may be an advantage for the treatment of AIDS-related KS where both proteins appear to contribute to the progression of the disease (42) .
